The suppression of N-linked glycosylation by tunicamycin has been previously reported to markedly reduce RTKs signaling and radiosensitized U251 glioma and BXPC3 pancreatic adenocarcinoma cell lines (both of which became resistant to EGFR–targeted therapies)24. This evidence concerns the gene EGFR and central nervous system cancer.